These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35791488)

  • 21. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.
    Marín-Palma D; Tabares-Guevara JH; Zapata-Cardona MI; Flórez-Álvarez L; Yepes LM; Rugeles MT; Zapata-Builes W; Hernandez JC; Taborda NA
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network.
    Araujo DB; Machado RRG; Amgarten DE; Malta FM; de Araujo GG; Monteiro CO; Candido ED; Soares CP; de Menezes FG; Pires ACC; Santana RAF; Viana AO; Dorlass E; Thomazelli L; Ferreira LCS; Botosso VF; Carvalho CRG; Oliveira DBL; Pinho JRR; Durigon EL
    Mem Inst Oswaldo Cruz; 2020; 115():e200342. PubMed ID: 33111751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation of SARS-CoV-2 from COVID-19 Patients and an Asymptomatic Individual.
    Hishiki T; Usui K; An T; Suzuki R; Sakuragi JI; Tanaka Y; Matsuki Y; Kawai J; Kogo Y; Hayashizaki Y; Takasaki T
    Jpn J Infect Dis; 2022 May; 75(3):277-280. PubMed ID: 34719530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19.
    de Almeida Marques DP; Andrade LAF; Reis EVS; Clarindo FA; Moraes TFS; Lourenço KL; De Barros WA; Costa NEM; Andrade LM; Lopes-Ribeiro Á; Coêlho Maciel MS; Corrêa-Dias LC; de Almeida IN; Arantes TS; Litwinski VCV; de Oliveira LC; Serafim MSM; Maltarollo VG; Guatimosim SC; Silva MM; Tsuji M; Ferreira RS; Barreto LV; Barbosa-Stancioli EF; da Fonseca FG; De Fátima Â; Coelho-Dos-Reis JGA
    Virus Res; 2024 Feb; 340():199291. PubMed ID: 38065303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening.
    Rodriguez K; Saunier F; Rigaill J; Audoux E; Botelho-Nevers E; Prier A; Dickerscheit Y; Pillet S; Pozzetto B; Bourlet T; Verhoeven PO
    J Trace Elem Med Biol; 2021 Dec; 68():126818. PubMed ID: 34274845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
    Ma Q; Pan W; Li R; Liu B; Li C; Xie Y; Wang Z; Zhao J; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Yang Z
    Pharmacol Res; 2020 Aug; 158():104850. PubMed ID: 32360580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication of SARS-CoV-2 in cell lines used in public health surveillance programmes with special emphasis on biosafety.
    Pawar SD; Kode SS; Keng SS; Tare DS; Diop OM; Abraham P; Sharma DK; Sangal L; Yadav PD; Potdar VA
    Indian J Med Res; 2022 Jan; 155(1):129-135. PubMed ID: 35859439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.
    Harfoot R; Lawley B; Hernández LC; Kuang J; Grant J; Treece JM; LeQueux S; Day R; Jack S; Stanton JL; Bostina M; Ussher JE; Quiñones-Mateu ME
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
    Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
    Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of Anti-SARS-CoV-2 Treatments Based on Curcumin, Used Alone or Employed as a Photosensitizer.
    Zupin L; Fontana F; Clemente L; Borelli V; Ricci G; Ruscio M; Crovella S
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens.
    Yadav PD; Gupta N; Potdar V; Mohandas S; Sahay RR; Sarkale P; Shete AM; Razdan A; Patil DY; Nyayanit DA; Joshi Y; Patil S; Majumdar T; Dighe H; Malhotra B; Shastri J; Abraham P
    Viruses; 2022 Feb; 14(3):. PubMed ID: 35336868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
    Runfeng L; Yunlong H; Jicheng H; Weiqi P; Qinhai M; Yongxia S; Chufang L; Jin Z; Zhenhua J; Haiming J; Kui Z; Shuxiang H; Jun D; Xiaobo L; Xiaotao H; Lin W; Nanshan Z; Zifeng Y
    Pharmacol Res; 2020 Jun; 156():104761. PubMed ID: 32205232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-SARS-CoV-2 Activity of a Polyphenolic Complex from Maackia amurensis.
    Krylova NV; Iunikhina OV; Fedoreev SA; Pott AB; Persiyanova EV; Mishchenko NP; Tarbeeva DV; Shchelkanov MY
    Bull Exp Biol Med; 2023 Dec; 176(2):187-190. PubMed ID: 38191881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Water Extract of the Chaga Medicinal Mushroom, Inonotus obliquus (Agaricomycetes), Inhibits SARS-CoV-2 Replication in Vero E6 and Vero Cell Culture Experiments.
    Teplyakova TV; Pyankov OV; Safatov AS; Ovchinnikova AS; Kosogova TA; Skarnovich MO; Filippova EI; Poteshkina AL
    Int J Med Mushrooms; 2022; 24(2):23-30. PubMed ID: 35446519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
    Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
    Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.